German Drug and Addiction Commissioner Backs Nicotine Pouch Ban, Calls for Stricter Regulation

Nov.22.2024
German Drug and Addiction Commissioner Backs Nicotine Pouch Ban, Calls for Stricter Regulation
Germany's Federal Drug and Addiction Commissioner has called for stricter enforcement of the nicotine pouch ban, highlighting shortcomings in the current implementation of youth protection regulations.

According to GMX on November 22, German Federal Drug and Addiction Commissioner Burkhard Blienert is pushing for a ban on nicotine pouches.

 

The commissioner stated in an interview with the German news agency: "Nicotine pouches are neither healthy nor safe. People can ingest large amounts of nicotine in a short period of time through them, and the product is highly addictive."

 

He believes that solely relying on youth protection laws is impractical, which has been validated in the current situation of disposable vapes.

 

Addiction counselors pointed out that nicotine pouches are becoming increasingly popular among students. Despite the products being banned from sale, they can still be purchased online. Prevention organizations criticized the lack of enforcement of the ban.

 

The coordinator of the Lower Saxony Addiction Office, Ricarda Henze, said, "The enforcement of laws protecting teenagers must be strictly monitored, and strict punishments should be imposed for violations."

 

Burkhard Blienert is the Commissioner for Drug and Addiction Policy of the Federal Government in Germany, and has been serving as the Federal Commissioner for Drugs in the Federal Ministry of Health under Chancellor Olaf Scholz's government since 2022.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Expert Warns in 2Firsts Op-ed: Proposed COP11 Ban on Nicotine Pouches Would Be a Global Public Health Mistake
Expert Warns in 2Firsts Op-ed: Proposed COP11 Ban on Nicotine Pouches Would Be a Global Public Health Mistake
As global delegates prepare for COP11, a leaked EU position paper has sparked fresh debate over the future of nicotine pouch regulation. In an exclusive op-ed submitted to 2Firsts, Dr. Nveed Chaudhary, Chair of GINN’s Scientific Committee, argues that banning nicotine pouches would be a profound public health mistake—one that ignores harm reduction science and risks reversing global progress in smoking cessation.
Nov.03
Philip Morris International Fails to Invalidate British American Tobacco Unit’s Vape Patent
Philip Morris International Fails to Invalidate British American Tobacco Unit’s Vape Patent
The European Patent Office’s Board of Appeal upheld British American Tobacco’s Nicoventures Trading Ltd. vape patent, rejecting Philip Morris International’s objections. The board ruled that the patent’s use of predefined heater activation parameters not based on user puffs was novel and valid.
Nov.10
Luxembourg Passes Bill 8333: Heated Tobacco and Nicotine Pouches Regulated
Luxembourg Passes Bill 8333: Heated Tobacco and Nicotine Pouches Regulated
Luxembourg’s Chamber of Deputies adopted Bill No. 8333, transposing EU Directive 2022/2100 and extending tobacco controls to heated tobacco, e-cigarettes and nicotine pouches. The law bans flavourings, restricts sales to minors, and caps nicotine content at 0.048 mg per pouch. CBD and caffeine additives are prohibited.
Nov.03 by 2FIRSTS.ai
Harm Reduction Experts Warn: FCTC COP11 Policies Risk Marginalizing the Global South
Harm Reduction Experts Warn: FCTC COP11 Policies Risk Marginalizing the Global South
Two global tobacco harm reduction experts, in their submission to 2Firsts, argue that several COP11 policy proposals driven by high-income countries do not align with the capacities and conditions of low- and middle-income countries. They highlight research and funding gaps and call for a more equitable global support mechanism.
Nov.19
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Advocates say the economic authority’s decision contradicts national health goals and violates a Supreme Court directive banning new tobacco ventures.
Oct.27 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai